Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcellaâs AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcellaâs AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering. Source
No articles found.
CannaKorp, Inc. is a technology start-up company that is simplifying and improving...
CannaKorp, Inc. is a technology start-up compan...
Luna (NASDAQ:LUNA) develops and manufactures new-generation products for the healt...
Luna (NASDAQ:LUNA) develops and manufactures ne...
As the leader womenâs health, we deliver life-changing and life-saving diagnosti...
As the leader womenâs health, we deliver life...
Quanterix is a company that is digitizing biomarker analysis with the goal of adva...
Quanterix is a company that is digitizing bioma...
Join the National Investor Network and get the latest information with your interests in mind.